Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).
Thomas Martin(University of California, San Francisco), Sundar Jagannath(Mount Sinai Hospital), Joris Diels(Janssen (Belgium)), Katja Weisel(Universität Hamburg), Satish Valluri(Janssen (United States)), Keqin Qi(Janssen (United States)), Jesús G. Berdeja(Tennessee Oncology), Arnob Banerjee(Johnson & Johnson (United States)), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Jordan M. Schecter(Centro de Investigación del Cáncer), Concetta Crivera(Janssen (Belgium)), Maneesha Mehra(Janssen (United States)), Sandhya Nair(Janssen (Belgium)), Anil Londhe(Janssen (United States)), Martin Vogel(Janssen (United States)), Carolyn C. Jackson(Centro de Investigación del Cáncer), Amrita Krishnan(City of Hope), Yunsi Olyslager(Janssen (Belgium))
Cited by 7
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k